Asset Sale Signals Precision Pathology sold lab assets to bioAffinity Technologies in September 2023 for $3.5M, signaling a strategic pivot and potential openness to partnerships, licensing of diagnostics technology, or collaboration on CyPath Lung development.

LDT Collaboration History The company has a track record licensing and developing CyPath Lung as a Laboratory Developed Test (LDT) through a licensing arrangement with bioAffinity Technologies since 2018, with ongoing development noted in 2020, indicating potential appetite for external collaborations and co-development deals.

Quality Control Advantage A rigorous QA process with two board-certified pathologists and a third external expert for disputes demonstrates high diagnostic quality and risk management; opportunity to offer AI-assisted pathology support tools, second-opinion platforms, or telepathology services to partner institutions.

Secure Reporting Portal HIPAA-compliant, web-based access to pathology reports enables physicians to retrieve results securely from anywhere; potential for integration services with EMR/LIS, data analytics, and digital workflow optimizations for health systems.

Regional Growth Potential San Antonio-based operation with strong physician-driven referrals and a reputation for fast turnaround; target expansion to Texas health systems and ambulatory networks through managed pathology services, remote/telepathology capabilities, or white-label pathology partnerships.